Fab'entech launches COVID-19 immunotherapy program
Lyon, France-based Fab’entech said today it has launched a program to develop an immunotherapy treatment against COVID-19.
This treatment will be used for severely ill patients requiring respiratory assistance. Human clinical trials should start in early 2021.
In order to meet new public health challenges, Fab’entech has created a development and production platform based on a polyclonal immunotherapy technology which enables targeted recognition of a virus or toxin and its specific neutralization. This new COVID-19 program stems from the R&D and industrial platform developed by Fab’entech over the last decade, which draws on technology proven in the treatment of infectious diseases.
Launched in 2009 on the basis of an immunotherapy process initially developed by Sanofi Pasteur for its own product and licensed to Fab’entech, the company has already developed a first treatment against avian flu H5N1 and worked, in particular, on a treatment for Ebola.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze